All products for:AMS Integrated SolutionAntibiotic Optimization InitiationAntimicrobial Resistance ManagementBacteriaBIOFIRE®FungiHealthcare-Associated InfectionsMolecular diagnosticsMultiplex testingBacterial infectionsReal-time amplificationCentralized testingSepsis ManagementFungal infectionsSepsis

BIOFIRE® Blood Culture Identification 2 (BCID2) Panel

The BIOFIRE® Blood Culture Identification 2 (BCID2) Panel enables rapid and accurate automated detection of pathogens and antibiotic resistance genes associated with bloodstream infections.

  • Simple: 2 minutes of hands-on time
  • Fast: Turnaround time of about 1 hour
  • Comprehensive: Simultaneously tests for 43 targets and identifies pathogens in more than 9 out of 10 positive blood cultures. BCID2 detects 10 antimicrobial resistance genes and emerging pathogens like C.auris and S.maltophilia
  • Accurate: The average positive agreement rate (or sensitivity) across all pathogens on the BCID2 panel is 99%, and the negative agreement rate (or specificity) is 99.8%1

1The stated performance is the aggregate of the prospective data from the clinical study.

Add to your selection

Do you need more information?

Contact us

Simple, comprehensive pathogen ID from blood cultures

The BIOFIRE® Blood Culture Identification 2 (BCID2) Panel tests for a comprehensive list of 43 pathogens and 10 antibiotic resistance genes associated with bloodstream infections. With just one test you can identify pathogens more than 9 out of 10 positive blood cultures in about 1 hour with only 2 minutes of hands-on time. The BIOFIRE®  BCID2 Panel is designed for the BIOFIRE® systems, an FDA, CE-IVD, and TGA certified multiplex PCR system that integrates sample preparation, amplification, detection and analysis.

  • Simple: 2 minutes of hands-on time
  • Fast: Turnaround time of about 1 hour
  • Comprehensive: Simultaneously tests for

    43 targets and identifies pathogens in more than

    9 out of 10 positive blood cultures. BIOFIRE BCID2 panel detects 10 antimicrobial resistance genes and emerging pathogens like C.auris and S.maltophilia
  • Accurate: The average positive agreement rate (or sensitivity) across all pathogens on the BCID2 panel is 99%, and the negative agreement rate (or specificity) is 99.8%2.

The BIOFIRE® BCID2 panel is one of six FDA-cleared and CE-marked panels for use on the BIOFIRE® systems. Taken together, the BIOFIRE® panels comprise the largest infectious disease pathogen menu commercially available. The other available panels are:

2The stated performance is the aggregate of the prospective data from the clinical study.

BIOFIRE® BLOOD CULTURE IDENTIFICATION 2 (BCID2) PANEL

1 Test. 43 Targets. ~1 Hour.

GRAM-NEGATIVE BACTERIA GRAM-POSITIVE BACTERIA
Acinetobacter calcoaceticusbaumannii complex

Bacteroides fragilis

Enterobacterales

  Enterobacter cloacae complex

  Escherichia coli

  Klebsiella aerogenes

  Klebsiella oxytoca

  Klebsiella pneumoniae group

  Proteus spp.

  Salmonella spp.

  Serratia marcescens

Haemophilus influenzae

Neisseria meningitidis

Pseudomonas aeruginosa

Stenotrophomonas maltophilia		 Enterococcus faecalis

Enterococcus faecium

Listeria monocytogenes

Staphylococcus spp.

  Staphylococcus aureus

  Staphylococcus epidermidis

  Staphylococcus lugdunensis

Streptococcus spp.

  Streptococcus agalactiae

  Streptococcus pneumoniae

  Streptococcus pyogenes
Yeast Antimicrobial Resistance Genes


Candida albicans

Candida auris

Candida glabrata

Candida krusei

Candida parapsilosis

Candida tropicalis

Cryptococcus (C. neoformans/C. gattii)

 

Carbapenemases

IMP

KPC

OXA-48-like

NDM

VIM



Colistin Resistance

mcr-1



ESBL

CTX-M



Methicillin Resistance

mecA/C

mecA/C and MREJ (MRSA)



Vancomycin Resistance

vanA/B

 

Fighting sepsis: a top healthcare challenge today

Early identification and treatment of sepsis is essential to combat one of the leading causes of hospital patient deaths3 [Sepsis Alliance 2018]. The International Guidelines for the Management of Sepsis and Septic Shock recommend empiric broad-spectrum therapy with one or more antimicrobials for patients presenting with sepsis or septic shock to cover all likely pathogens within 1 hour of recognition of the disease4 . However, it is estimated that early empiric antibiotic therapy is inappropriate in about 30% of patients5 . Moreover, it is best practice according to the Guidelines3 to narrow down antimicrobial therapy as soon as pathogens are identified, in order to reduce the occurrence of antimicrobial resistances.

Obtaining rapid blood culture organism identification, combined with the local antibiogram, allows for the timely adjustment of a broad-spectrum empiric antimicrobial therapy to a narrow, targeted patient treatment6.

The BIOFIRE® BCID2 Panel can provide the essential combination of speed, accuracy and comprehensiveness to enable a rapid, definitive identification of a pathogen directly from positive blood cultures..

The potential benefits of fast and comprehensive testing of bloodstream infections may include guided appropriate antibiotic therapy, decreased hospital length of stay7, reduced hospital costs and reduced patient morbidities and mortality.

 

1The stated performance is the aggregate of the prospective data from the clinical study.

2The stated performance is the aggregate of the prospective data from the clinical study.

3Sepsis Alliance: Sepsis Fact Sheet 2018. https://www.sepsis.org/wp-content/uploads/2017/05/Sepsis-Fact-Sheet-2018...

4Rhodes et al., Intensive Care Med. 2017 Mar;43(3):304-377

5Zhang D, et al. Critical Care Medicine 2015;43(10):2133-2140

6Banerjee R, et al. Clinical Infectious Diseases 2015;61:1071-80

7Ray et al. Pediatr Infect Dis J 2016;35:e134-138

Panel Specifications

Sample Handling Performance Parameters
Sample Type: positive Blood Culture media Hands-on time: approximately 2 minutes
Sample Volume: 200 μL Turnaround time: about 1 hour

 

Our Solutions

 

Publications

Randomized Trial of Rapid Multiplex Polymerase Chain Reaction-Based Blood Culture Identification and Susceptibility Testing

Banerjee R., Teng C.B., Cuningham S.A., Ihde S.M., Steckelberg J.M., Moriarty J.P., Shah N.D., Mandrekar J.N., Patel R.

CLINICAL INFECTIOUS DISEASES 2015;61(7):1071-1080

Rapid Identification of Pathogens from Pediatric Blood Cultures by Use of the FilmArray® Blood Culture Identification Panel.

Zheng X., Polanco W., Carter D., Shulman S.

JOURNAL OF CLINICAL MICROBIOLOGY 2014;52(12):4368-71.

The impact of a rapid molecular identification test on positive blood cultures from critically ill with bacteremia: A pre-post intervention study.

Verroken A., Despas N., Rodriguez-Villalobos H., Laterre P.-F. PLoS One. 2019; 14(9): e0223122.

Multi-center Evaluation of the BioFire® FilmArray® Blood Culture Identification 2 Panel for the Detection of Microorganisms and Resistance Markers in Positive Blood Cultures.

Lu Y., Hatch J., Holmberg K. et al. ID WEEK 2019, Washington D.C. Abstract #651

 

Testimonials

Watch Dr Hani Shukri’s testimonial on the implementation of the BioFire BCID panels at the King Abdulaziz University Hospital in Saudi Arabia

 

Technical Notes:

Instructions for Use and Manuals:

Product Support Documents:

EC Declarations of conformity:

Please consult your local bioMérieux representative for product availability in your country

Pioneering diagnostics